Stay in touch
Prime news from our network.
#read
Isomorphic Labs receives 600 million dollars for AI-supported drug research
The British company Isomorphic Labs, which specialises in artificial intelligence, has received 600 million US dollars in its first external financing round. The round was led by Thrive Capital with an investment from GV and additional capital from the previous main investor Alphabet.
03/04/2025
The aim of Isomorphic Labs is to fundamentally change drug development with the help of novel AI models. The specially developed AI engine is designed to enable biomedical breakthroughs and accelerate new therapies in various medical fields. A central element is the AlphaFold 3 model developed jointly with Google DeepMind, which can accurately predict molecular structures and interactions. The company is already working with pharmaceutical giants Eli Lilly and Novartis and is pursuing its own projects, for example in the fields of oncology and immunology. Isomorphic Labs intends to use the new funding to expand its team, drive forward the clinical development of its own programmes and further expand its AI platform. Founder and CEO Sir Demis Hassabis sees this as a decisive step towards achieving the long-term goal of combating all diseases with AI.
The above texts, or parts thereof, were automatically translated from the original language text using a translation system (DeepL API).
Despite careful machine processing, translation errors cannot be ruled out.